Breathe Life Sciences (BLS) parent Bioxyne has signed a manufacturing and supply agreement with existing customer, NectarTek Australia.
Based on committed volumes, BLS told the ASX it expects to generate at least A$7 million in sales from NectarTek in FY26.
The contract includes minimum orders of pastilles ($3.6m), flower products ($2.5m), vapes ($500k), and oral mucosal oils and other products ($500k). The agreement may be terminated with six months’ written notice.
NectarTek is an Australian healthcare company and wholesale pharmaceutical distributor which operates clinics across Australia, the UK and Germany.
It has committed to ordering the quantities in FY26 with the minimum order value representing a 200% increase on historical orders from the company.
Bioxyne CEO Sam Watson said: “This agreement with NectarTek underscores market trust in BLS and our ability to deliver value to industry partners, clients, and stakeholders. Exclusivity is a privilege we have earned by consistently delivering results and supporting our clients’ growth.”
The firm said it anticipates securing additional long-term contracts following a substantial increase in manufacturing capacity across all product categories with the potential to generate revenue of more than $100m per year.
